2013 Annual Meeting | Criteria for Stopping and Starting Multiple Sclerosis Therapy

�鶹��ýӳ��

2013 Annual Meeting | Criteria for Stopping and Starting Multiple Sclerosis Therapy

Date Sunday 03/17/13

Time 06:30 AM - 09:30 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Extended Seminar

Director(s) Mark Keegan, MD, F�鶹��ýӳ��

Topic(s)

Learning Objectives Participants should be familiar with some of the variables and difficulties involved in deciding when to start treatment with disease-modifying therapies in RRMS and when to stop such treatments in persons possibly no longer benefiting from them.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
06:30 AM - 07:10 AM		Clinical Importance of Relapses in Multiple Sclerosis Helen Tremlett, PhD, BPharm
07:10 AM - 07:50 AM		When to Start Disease Modifying Therapy in RRMS Brian G. Weinshenker, MD, F�鶹��ýӳ��
07:50 AM - 08:10 AM		Discussion
08:10 AM - 08:30 AM		Break
08:30 AM - 09:10 AM		Stopping and Changing MS Therapies Mark Keegan, MD, F�鶹��ýӳ��
09:10 AM - 09:30 AM		Questions and Answers

Faculty Disclosures
Mark Keegan, MD, F�鶹��ýӳ��	Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care.
Helen Tremlett, PhD, BPharm	Dr. Tremlett has nothing to disclose.
Brian G. Weinshenker, MD, F�鶹��ýӳ��	Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zenas Pharma. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.